MALT Lymphoma Prognostic Index (MALT-IPI)

ورودی‌های بالینی بیمار

حداقل ۱۸ — حداکثر ۱۲۰ • واحد: years

پنل نتیجه و تصمیم بالینی
در انتظار ورودی‌ها
malt ipi score
—points
آماده برای ارزیابی

پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.

طبقات خطر و بازه‌های امتیاز:
  • Low Risk0–0
  • Intermediate Risk1–1
  • High Risk2–3
Direct Clinical Answer

The MALT Lymphoma Prognostic Index (MALT-IPI) calculates determining thromboembolic risk, heparin-induced thrombocytopenia probability, and bleeding diathesis. Key inputs include age. Scores guide initiating targeted anticoagulation therapy, platelet monitoring, or hematology specialist referral. This standardized assessment improves clinical decision safety and bedside patient management.

Clinical Guidelines & Evidence

Identifies MALT lymphoma patients at risk for poor outcomes using three clinical parameters: age ≥70 years, Ann Arbor stage III/IV, and elevated lactate dehydrogenase (LDH). Stratifies patients into low, intermediate, and high risk groups predictive for event-free survival and overall survival.

Clinical Indication

The MALT Lymphoma Prognostic Index (MALT-IPI) is indicated for bedside clinical practice to support Identifies MALT lymphoma patients at risk for poor outcomes using three clinical parameters: age ≥70 years, Ann Arbor stage III/IV, and elevated lactate dehydrogenase (LDH). Stratifies patients into low, intermediate, and high risk groups predictive for event-free survival and overall survival.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

Target Population

Target population comprises Patients presenting with coagulopathy, thrombocytopenia, venous thromboembolism (DVT/PE), or hematologic neoplasms. Clinical application is indicated across Hematology-oncology services, bone marrow transplant units, anticoagulation clinics, and acute medical wards.

Limitations & Contraindications

Severe thrombocytopenia with concomitant microvascular thrombosis (TTP, HIT, DIC) represents a medical emergency requiring rapid intervention.

Clinical Pearls & Action Plan

Detailed history of heparin exposure, platelet count kinetics, and comprehensive coagulation profiles are vital in consumptive coagulopathies. Guideline pearl: Prognostic utility retained across different treatment arms (chlorambucil, rituximab, rituximab plus chlorambucil).

Formula & Variables:

MALT-IPI Score = Age points + LDH points + Ann Arbor Stage points. Age ≥70 years (1 point), elevated LDH (1 point), Ann Arbor stage III/IV (1 point). Total score 0 = Low risk, 1 = Intermediate risk, ≥2 = High risk.

Input Parameters

NameTypeRequiredDescription
ageintegerYesPatient age in years. Age ≥70 years is associated with worse prognosis (HR 1.72, 95% CI 1.26-2.33)(years)
ldh_levelstringYesSerum lactate dehydrogenase (LDH) level relative to upper limit of normal. Elevated LDH is associated with worse prognosis (HR 1.87, 95% CI 1.27-2.77)
ann_arbor_stagestringYesAnn Arbor staging system for lymphomas. Stage III/IV disease is associated with worse prognosis (HR 1.79, 95% CI 1.35-2.38)

Score Interpretation & Guidance

RangeStageDescription
0–0Low RiskLow risk of poor outcomes
1–1Intermediate RiskIntermediate risk of poor outcomes
2–3High RiskHigh risk of poor outcomes

Evidence-Based References (EBM)

  • Thieblemont C, Cascione L, Conconi A, Kiesewetter B, Raderer M, Gaidano G, et al. A MALT lymphoma prognostic index. Blood. 2017 Sep 21;130(12):1409-1417. doi: 10.1182/blood-2017-03-771915.DOI: 10.1182/blood-2017-03-771915
  • Hong J, Lee Y, Park J, Kim SJ, Lim ST, Kim JS, et al. Validation of the MALT-lymphoma international prognostic index (MALT-IPI) and extension of the prognostic model with the addition of β2-microglobulin. Ann Hematol. 2019 Nov;98(11):2499-2507. doi: 10.1007/s00277-019-03808-x.DOI: 10.1007/s00277-019-03808-x
  • Zucca E, Conconi A, Martinelli G, Bouabdallah R, Tucci A, Vitolo U, et al. Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Agent Alone. J Clin Oncol. 2017 Jun 10;35(17):1905-1912. doi: 10.1200/JCO.2016.70.6994.DOI: 10.1200/JCO.2016.70.6994

Related calculators